Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 4, 2014, Pages 331-339

  Graham, David J ^a   Zhou, Esther H ^a   Mckean, Stephen ^b   Levenson, Mark ^a   Calia, Katlyn ^b   Gelperin, Kate ^a   Ding, Xiao ^a   Macurdy, Thomas E ^b,c   Worrall, Chris ^d   Kelman, Jeffrey A ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Acumen LLC   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Centers for Medicare and Medicaid Services   (United States)

Author keywords

Angiotensin receptor blockers (ARBs); Cardiovascular; Mortality; Olmesartan; Pharmacoepidemiology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; OLMESARTAN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART FAILURE; HOSPICE CARE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; VERY ELDERLY; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STATISTICS AND NUMERICAL DATA; TIME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TETRAZOLES; TIME FACTORS; UNITED STATES;

EID: 84897545609     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3548     Document Type: Article

References (21)

1. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
2. Imai E, Chan JCN, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled trial. Diabetologia 2011; 54: 2978-2986.
3. Centers for Medicare and Medicaid Services. Medicare program general information. (Accessed July 22, 2011 at http://www.cms.hhs.gov/MedicareGenInfo/)
4. Centers for Medicare and Medicaid Services. Prescription drug coverage-general information. (Accessed July 22, 2011 at http://www.cms.hhs.gov/PrescriptionDrugCovGenIn/)
5. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
6. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28: 3083-3107.
7. Petersen LA, Wright S, Normand ST, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med 1999; 14: 555-558.
8. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 1999; 15: 1277-1282.
9. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002; 144: 290-296.
10. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99-104.
11. Choma NN, Griffin MR, Huang RL, et al. An algorithm to identify incident myocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf 2009; 18: 1064-1071.
12. Chung CP, Murry KT, Stein CM, et al. A computer algorithm for sudden cardiac death. Pharmacoepidemiol Drug Saf 2010; 19: 563-572.
13. Tirschwell DL, Longstreth WT. Validating administrative data in stroke research. Stroke 2002; 33: 2465-2470.
14. Roumie CL, Mitchel E, Gideon PS, et al. Validation of ICD-9 codes with a high positive predictive value for incident stroke resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf 2008; 17: 20-26.
15. Kokotaila RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revision 9 and 10. Stroke 2005; 36: 1776-1781.
16. Hill ME, Rosenwaike I. The Social Security Administration's Death Master File: the completeness of death reporting at older ages. Soc Secur Bull 2001/2002; 64: 45-51. (Accessed July 22, 2011 at http://www.socialsecurity.gov/policy/docs/ssb/v64n1/v64n1p45.pdf.)
17. Storer BE, Gooley TA, Jones MP. Adjusted estimates for time-to-event endpoints. Lifetime Data Anal 2008; 14: 484-495.
18. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009; 18: 67-80.
19. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-581.
20. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219-220.
21. Weiss NS. Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread? Cancer Epidemiol Biomarkers Prev 2008; 17: 1297-1299.